Introduction {#S1}
============

Chronic kidney disease (CKD) is gradually emerging as an important health care problem all over the world. The noted increase in its prevalence is partly due to a real increase in incidence, a better detection of CKD and a better survival of patients with renal insufficiency due to secondary causes (age, diabetes, cardiovascular disease) \[[@R1]\]. As early as 1984, Ratcliffe *et al*. \[[@R2]\] demonstrated that late referral (LR) of patients with progressive end-stage renal disease (ESRD) was a major reason for higher morbidity, mortality, cost and lower quality of life. Ever since, numerous studies have been carried out on this issue \[[@R3]\], confirming the same detrimental consequences related to LR. It is speculated that improving referral pattern will result in better outcomes of renal replacement therapy (RRT), but studies to validate whether such projects are feasible and cost-effective on a larger scale are still scant.

This paper aims to provide an in-depth review on our current understanding of the prevalence, causes, consequences and solutions for the problem of LR of ESRD patients.

An accurate definition of 'Late Referral' {#S2}
=========================================

There is no universally accepted definition of 'LR' of patients with CKD \[[@R6]\]. Nearly all authors have used the time of follow-up by a nephrologist before initiation of renal replacement as a measure to define LR. This criterion starts from the premise that it is the preparation for RRT, in particular the creation of a dialysis access, which is of importance to explain the higher morbidity in LR patients.

Depending on the study, different numbers of months prior to the initiation of dialysis (1, 3, 6 months or even 12 months) have been used to define LR of patients with CKD (see Table [1](#T1){ref-type="table"}). Apart of the term 'LR', some authors even define a subgroup of 'ultra-late referred patients' in whom dialysis is initiated within 1 month after referral \[[@R9]\]. A period of 3--4 months before initiation of dialysis is most widely accepted to discriminate between early and LR; however, this definition is arbitrary and the evidence to support it is lacking. As maturation of a native AV fistula takes time, a period of 4 months, based on this consideration, seems plausible. In the same line of reasoning, some authors, e.g. the DOPPS registry \[[@R10]\], use the presence of functioning permanent vascular access at the start of RRT as the criterion for defining 'early referral'.

###### 

Studies analysing referral for dialysis

  Reference                                    Time period                        Number                                      Definition of LR                                     \% of LR patients                                          Mortality                                                                                     PD//HD                                   Hospitalization                                                                              Special remarks
  -------------------------------------------- ---------------------------------- ------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Cass \[[@R32]\] 2002, AUS/NZ                 1 April 1995--31 December 1998     4234                                        3 months before RRT                                  26%                                                        Hazard ratio 1.19/95% CI                                                                      NA                                       NA                                                                                           Excluded unavoidable LR 3.5%; % of transplanted patients
  Schwenger \[[@R26]\] 2006, Austria/Germany   1 January 1998--31 December 2001   280                                         17 weeks before RRT                                  39.6%                                                      LR 34.2% versus ER 5.5% within 1 year                                                         PD: 18.2% Austria, 10.2% Germany         LR 16 days (4--104), ER 11 days (4--32)                                                      Two-centre study
  Roderick \[[@R15]\] 2002, UK                 1 June 1996--31 May 1997           361                                         4 months prior to RRT                                35%                                                        Death within 6 months                                                                         NA                                       10 days                                                                                      Differentiation unavoidable/avoidable
                                                                                                                              1 month prior to RRT                                 23%                                                        16%                                                                                                                                    18 days                                                                                      
                                                                                                                                                                                                                                              32%                                                                                                                                                                                                                                 
  Winkelmayer \[[@R50]\] 2001, USA             January 1991--June 1996            3014                                        3 months prior to RRT                                35%                                                        NA                                                                                            78% HD, 22% PD                           NA                                                                                           Determinants given for initial modality choice and switch
  Nakamura \[[@R69]\] 2007, Japan              1983--2003                         366                                         6 months prior to RRT                                47%                                                        Death within 1 year after start of RRT                                                        NA                                       NA                                                                                           Single centre
  Wauters \[[@R70]\] 2004, France              November 1999--March 2001          279                                         6 months prior to RRT: ER                            71.6%                                                      NA                                                                                            ER 13.5%, LR 13.9%                       NA                                                                                           Region wide, multi-centre study
                                                                                                                              6--1 months: intermediate reference                  15.1%                                                                                                                                                                                                                                                                                          
                                                                                                                              Less than 1 month: LR                                13.3%                                                                                                                                                                                                                                                                                          
  Sesso \[[@R71]\] 1996, Brazil                October 1992--March 1995           184                                         1 month prior to RRT                                 57%                                                        Survival rate: LR 69%, ER 87%; hazard ratio 2.77                                              LR 2.8%. ER 5.1%;                        NA                                                                                           
                                                                                                                                                                                                                                                                                                                                            iPD LR 23.6%, ER 32.1%                                                                                                                
  Górriz \[[@R72]\] 2002, Spain                1996--97                           362                                         6 months prior to RRT                                37.3%                                                      6-month survival rate: LR 10.2%, ER 3.2%; 3 years mortality: LR 36.9%, ER 24.9%               ER/planned 18.3% PD, uPL LR: 5.1%        ER 4.0 days (± 6.2 days), LR 17.7 (±14.6 days)                                               Multi-centre study, planned and unplanned referrals
  Metcalfe \[[@R73]\] 2000, Scotland           October 1997--September 1998       533                                         Planned and unplanned referral                       24.6% unplanned referral                                   Hazard ratio: unplanned 3.6 (1.4--9.3)                                                        23% of 90 days survivors started on PD   Planned 3 days (0--94 days), unplanned 9 days (0--124 days)                                  Planned/unplanned, no recovery from ARF
  Roubicek \[[@R43]\] 2000, France             January 1989--December 1996        270                                         4 months prior to RRT                                31%                                                        Not significant                                                                               NA                                       NA                                                                                           
  Schmidt \[[@R74]\] 1998, USA                 January 1990--April 1997           238                                         1 month prior to RRT                                 35%                                                                                                                                                                                                                                                                                            
  Ifudu \[[@R75]\] 1999                        1990--94                           220                                         No nephrological care                                57%                                                                                                                                                                                                                                                                                            
  Sesso \[[@R40]\] 1996, Brazil                October 1992--March 1995           184                                         1 month prior to RRT                                 57%                                                        Survival rate: LR 69%, ER 87%; hazard ratio 2.77                                              LR 2.8%. ER 5.1%;                        NA                                                                                           
                                                                                                                                                                                                                                                                                                                                            iPD LR 23.6%, ER 32.1%                                                                                                                
  Korevaar \[[@R76]\] 2001, The Netherlands    January 1997--May 1999             253                                         1 month prior to RRT                                 37%                                                        Hazard ratio 1.66                                                                                                                                                                                                                   
  Astor \[[@R65]\] 2001, USA                   October 1995--June 1996            356                                         1 month prior to RRT                                 25%                                                                                                                                                                                                                                                                                            
  Lameire \[[@R77]\] 1997, Europe              January 1993--December 1995                                                    1 month prior to RRT                                 35%                                                                                                                                                                                                                                                                                            
  Van Biesen \[[@R78]\] 1998, Europe           January 1996--December 1997                                                    1 month prior to RRT                                 29%                                                        Deaths in the LRs 26.7 versus 16.4%                                                           23% LR on PD, ER 49% on PD               Late versus early referrals (15.1 ± 16.0 versus 27.8 ± 23.7 days)                            
  Khan \[[@R79]\] 1994, UK                                                        304                                         Referred and non-referral to specialist                                                                         2-year survival rate: 58.7% referred, 25% non-referred patients                                                                                                                                                                     
  Navaneethan \[[@R80]\] 2007, USA             March 2003--March 2005             204                                         GFR \<15 ml/min: LR (CKD V), CKD I- IV: ER           22%                                                        1-year survival rate: LR 18%, ER 9%                                                           NA                                       NA                                                                                           
  Obialo \[[@R9]\], 2005, USA                  1999--2002                         460                                         3 months prior to RRT: LR, under 1 month: ultra LR   46% ultralate referred, 37% LR                             Mortality 40% ULR versus 15% ER and 26% LR                                                    NA                                       NA                                                                                           Socioeconomic implications
  Steel \[[@R81]\] 2002, USA                   1996--2000                         494                                         Referral 3 months prior to RRT                                                                                                                                                                                                                                                                                                                      Sociodemographic factors for LR
  Abderrahim \[[@R82]\] 2001, Tunesia          1990--96                           299                                         NA                                                   29--36%                                                    NA                                                                                            NA                                       NA                                                                                           Subgroup analysis: diabetes leading to ESRD
  Bhan \[[@R83]\] 2007, Canada                 1 year                             93                                          3 months prior to RRT                                48%                                                        NA                                                                                            NA                                       NA                                                                                           Analysis on vascular access
  Curtis \[[@R84]\] 2005, Canada/Italy         1997--1998/1999--30 June 2002      288                                         3 months prior to RRT                                NA                                                         Standard nephrology clinic versus multi-disciplinary clinic attendance (hazards ratio 2.17)   ER patients 40% PD, 60% HD               NA                                                                                           Includes only ER patients, analysis of multi-disciplinary clinic care
  Frimat \[[@R86]\] 2004, France               1997--99                           508 // 148 patients with diabetes type II   3 months prior to RRT                                27%                                                                                                                                                      75% HD, 25% PD                           NA                                                                                           Subgroup analysis: type II diabetes leading to ESRD
  Kazmi WH \[[@R85]\] 2004, USA                1996--97                           2195                                        4 months prior to RRT                                33%                                                        Hazard ratio 1.44 from LR death within 1 year                                                 53% ER 40% LR                            NA                                                                                           WAVE II study
  Lorenzo \[[@R87]\] 2004, USA                 1998--2003                         538                                         3 months prior to RRT: planned presentation          281 planned patients (52%), 257 unplanned patients (48%)   Unplanned presentation hazard ratio (HR), 1.73                                                NA                                       All-cause hospitalization (incidence rate ratio, 1.56; 95% CI, 1.36 to 1.79; *P* \< 0.001)   Differentiation planned/ unplanned
  Riegel \[[@R88]\] 2005, Germany              July 2002--March 2003              551                                         CKD IV: ER                                           58% referred late: CKD V                                   NA                                                                                            NA                                       11.4 days ER, 17.4 days LR                                                                   
  Ellis \[[@R89]\] 1998, UK                    1996--97                           198                                         3 months prior to RRT                                32% LR                                                     12-month survival 60.5% versus 72.5%                                                          NA                                       25 days LR versus 9.7 days ER                                                                
  Avorn \[[@R36]\] 2002, USA                   1991--96                           3014                                        3 months prior to RRT                                34.5%                                                      37% increase in risk of death in the first year of dialysis                                   NA                                       NA                                                                                           
  Castellano \[[@R90]\] 2006, Spain            2003--04                           117                                         Planned and unplanned                                44% unplanned, 56% planned                                 6-month mortality 4.6% versus 11.5%                                                           NA                                       23.6 days unplanned, 3 days                                                                  
  Gallego \[[@R91]\] 2003, Spain               1994--98                           139                                         6 months prior to RRT                                23%                                                        Mean survival time: 73.6 ± 4.3 months (ER) and 73.0 ± 6 months (LR)                           NA                                       NA                                                                                           
  GIMEP \[[@R92]\] 2002, Italy                 1998--99                           1137                                        2 months prior to RRT                                45%                                                        NA                                                                                            44% ER, 9.1% LR                          NA                                                                                           Multi-centre study
  Gøransson \[[@R93]\] 2001, Norway            1984--98                           242                                         3 months prior to RRT                                27%                                                        NA                                                                                            NA                                       31 days LR, 7 days ER                                                                        
  Lhotta \[[@R94]\] 2003, Austria              January 1999-- October 2000        75                                          GFR dependent: referral when GFR \<20 ml: LR         56%                                                        2-year follow-up: 45% deaths LR, 24% ER                                                       NA                                       NA                                                                                           
  Lin \[[@R95]\] 2003, Taiwan                  February 1988--June 2001           115                                         6 months prior to RRT                                53%                                                        5-year follow-up: ER: 72.4%; LR: 35.2%                                                        NA                                       NA                                                                                           Subgroup analysis of type II diabetes
  Pena \[[@R96]\] 2006, Spain                  January 1990 to December 2001      178                                         4 months prior to RRT                                22%                                                                                                                                                      NA                                       NA                                                                                           

Definitions based on time-to-start of dialysis or the presence of functioning permanent access ignore, however, the large group of patients with impaired renal function, in whom the intervention of a nephrologist can be of use to slow down progression and treat secondary complications. Therefore, a 'narrow definition' based on time-to-start of dialysis might seriously underestimate the impact of LR, as it is well established that the majority of CKD stage 3 patients will die because of cardiovascular diseases even before they will reach ESRD \[[@R11]\]. As a consequence of LR, many of CKD stage 3 patients are deprived of the available prophylactic strategies to slow down the progression of renal disease and the linked cardiac comorbidity. It would thus be more appropriate to define 'LR' as patients not referred according to the existing guidelines, such as those of the Royal College of General Practitioners in the UK, or of the 'The National Kidney Foundation---Kidney Disease Outcomes Quality Initiatives guidelines' \[[@R12]\]. Apparently, knowledge about these criteria is not widespread amongst or implemented by medical practitioners. Agarwal *et al*. \[[@R13]\] demonstrated that internal medicine residents have widely differing perceptions of indications for nephrology referral. A few residents chose nephrology referral for proteinuria (45%), uncontrolled hypertension (64%) or hyperkaelaemia (26%). Twenty-eight percent of the residents considered consulting a nephrologist for anaemia of CKD, whereas 45% would do so for bone and mineral disorders. Most of the residents would only involve a nephrologist when estimated glomerular filtration rate (eGFR) was \<30 ml/min/1.73 m^2^ or for a rapid decline in GFR (79%). Whereas most residents would refer a patient for dialysis initiation at an eGFR between 15 and 30 ml/min/1.73 m^2^ (59%), 18% would only do so when eGFR was \<5 ml/ min/1.73 m^2^.

Nevertheless, the use of a broader definition is essential, as this will create more opportunities for intervention and prevention of ESRD. In view of the expected patient numbers, this will change our approach to these patients from an individual patient--nephrologist relationship, to a more structured approach using 'CKD clinics', where the workload is distributed amongst a multi-disciplinary team, using predefined programmes and nurse specialists \[[@R14]\].

Reasons for LR {#S3}
==============

Lameire *et al*. \[[@R8]\] identified some potential reasons for LR: non-awareness of a renal disease until the patient develops uraemic symptoms and the lack of or inadequate routine screening of patients at high risk of developing a renal insufficiency (such as hypertension or diabetes).

Roderick *et al*. \[[@R15]\] point out that we should discriminate two major groups of LRs: those in whom LR was avoidable and those where it was not. 'Avoidable' LR occurs in patients with a slow and constant progression of their underlying kidney disease, among whom the start of RRT could have been easily anticipated. There is some indication that for this latter patient group, there is a small decrease in the prevalence of LR, as a consequence of the augmented awareness for ESRD \[[@R17]\]. The routine measurement of proteinuria has already proven to be of benefit especially in this group of patients, but its use is not yet generally implemented. Another potential pitfall in the screening of patients for kidney disease is the limitation of the commonly used screening marker creatinine \[[@R18]\]. The attentiveness towards a declining, or even already alarmingly decreased, renal capacity can be improved by introducing the estimated 'Modification of diet in Renal Disease' (MDRD) formula-based glomerular filtration rate (eGFR) into the laboratory reports as a standard parameter instead of simple creatinine values \[[@R17]\]. In an Australian study, this method leads to an improvement of the referral patterns \[[@R19]\]. There is, however, substantial concern that the implementation of automatic eGFR reporting by labs would result in a 'tsunami' of (mostly elderly and frail) patients, and this as a consequence of the inaccuracies of the estimation formulae and the physiological decline of kidney function with age \[[@R20]\]. It is argued that many of these patients do not have real kidney disease, but rather 'renal impairment', and that nephrology referral is, therefore, pointless. Although this reasoning is in itself correct, it should not be forgotten that especially in this frail population with multiple comorbidities, avoidance of acute-on-chronic deterioration of kidney function by inappropriate investigations (e.g. radio-contrast) or medication (e.g. non-steroidal agents) is of utmost importance. In consideration of the growing number of patients developing chronic kidney disease, this constant percentage of patients at high risk of acute-on-chronic renal failure implies an immense impact on the socioeconomic situation in the coming years. Strategies to educate general physicians and to define and implement accurate criteria, based upon proper and reliable screening tools, for nephrology referral should be developed.

Some patients, however, suffer from a rapid deterioration of their initially mildly abnormal kidney function, either because of an acute intercurrent illness, e.g. rapidly progressive glomerulonephritis, or because of a sudden deterioration of their underlying CKD (acute-on-chronic renal failure), e.g. a contrast-induced nephropathy (CIN) in a patient with risk factors for CIN such as diabetes or hypovolaemia.

For the patients with an acute illness, LR is by definition unavoidable. For the second group, the implementation of the 'broad' definition of LR and a multi-disciplinary approach could potentially lead to avoidance of a substantial number of these cases. In a European survey \[[@R23]\], only a limited number of patients had a follow-up between 1 and 3 months before the start of dialysis, resulting in a 'hyperacute' referral of most of the patients. This would necessitate nephrology units to establish large 'information campaigns' for general practitioners and specialists such as cardiologists, diabetologists, vascular surgeons, etc. to screen for earlier stages of CKD.

There is evidence that LR is negatively influenced by socioeconomic factors, ethnicity \[[@R24]\], age and presence of comorbidities \[[@R7]\]. It can be speculated that in older, frailer patients, referral is delayed as general practitioners misinterpret the possibilities and merits of eventual interventions, such as dialysis. This can result in non-referral \[[@R14],[@R26],[@R27]\] or hyperacute referral \[[@R28]\]. However, it has been clearly demonstrated that even in e.g. the elderly, LR results in worse outcome \[[@R26]\]. The LR of these 'borderline' patients also raises ethical questions: as the specialist does not know the patient, advanced care planning cannot be established, and most specialists will give the patient the benefit of the doubt and start RRT \[[@R30]\]. Again, as most of the comorbidities, such as diabetes and cardiovascular disease, can be a cause of or be linked to renal impairment, it should be recommended that general physicians are educated properly about the interactions of these comorbidities, and about the outcome of different treatment options, not only in terms of survival but also in terms of quality of life. Whereby the existence of communication channels between general practitioners and specialists seem to improve early referral.

Prevalence of LR {#S4}
================

Although the detrimental effect of LR has been highlighted for many years \[[@R29],[@R31],[@R32]\], the prevalence of late referred patients among the patients in whom dialysis is initiated can be regarded as constantly fluctuating around 30% (see Table [1](#T1){ref-type="table"}). In addition, even very recent studies report that LR and non-elective start of dialysis remain a frequent finding \[[@R7],[@R33]\]. The phenomenon appears to exist throughout all industrialized as well as developing countries \[[@R29],[@R33]\] and alike in adults, the elderly and paediatric patients \[[@R26],[@R34]\].

In a French study \[[@R35]\], 23% of the patients were referred less than 1 month before the start of dialysis and 8% were referred only 1--4 months before dialysis. In the United States, Avorn *et al*. \[[@R36]\] and Stack *et al*. \[[@R37]\] report similar numbers of late referred patients (34% of 2398 and 33% of 2264 investigated patients). In a UK \[[@R15]\] and a German \[[@R26]\] investigation, 37% and 40--60% of patients were referred shorter than 4 and 2 months before the start of dialysis, respectively. Studies from developing countries \[[@R38]\] report even higher numbers of late referred patients, although the reasons for this differ from those of industrialized countries, as economic factors and lack of medical infrastructure, might here be the driving forces.

Differences in outcome between late and early referred patients {#S5}
===============================================================

The late referred patient is often in a challenging clinical condition, often with pulmonary congestion or hyperkaelaemia, necessitating immediate RRT.

But it is not only the hyperacute situation that is causing an increased mortality in this group of patients: the late referred patient presents with already chronic and numerous clinical, haematological, hormonal and metabolic abnormalities, such as anaemia, malnutrition, hyperparathyroidism, hyperphosphataemia, hypocalcaemia, hypertension and congestive heart failure, all of which have been linked to poor dialysis outcomes \[[@R39]\]. Furthermore, late referred patients are described less ACE inhibitors, ARBs and vitamin D analogues, although their beneficial effects are well proven. Sesso *et al*. \[[@R40]\] found a higher number of malnutrition, infective episodes, pulmonary oedema and severe hypertension in late referred patients. Jungers *et al*. \[[@R41]\] observed that in late referred patients the mean systolic and diastolic blood pressures were higher than those in controls, and fluid overload with pulmonary oedema was more often present; also plasma concentrations of phosphate were higher, while plasma levels of bicarbonate, haemoglobin, serum albumin and calcium were lower. Each of these parameters is potentially modifiable and begins its detrimental effect already during the pre-ESRD period \[[@R39]\]. It seems rational that attention to these abnormalities before dialysis initiation has a positive impact on long-term patient outcomes.

Van Biesen *et al*. \[[@R23]\] reported that during the first year after the start of renal replacement, mortality was nearly twice as high in the late versus early referred patients (28.9% versus 8.5%, *P* \< 0.05). Lin *et al*. \[[@R42]\] found that early referral was a positive and independent predictor of clinical outcome determining long-term prognosis in ESRD as well in HD as in PD, a finding corroborated by Cass *et al*. \[[@R32]\] who found that even after 5 years, mortality was higher in the late referred group.

Roubicek *et al*. \[[@R43]\] did not find a greater risk of death 1 year after initiation of dialysis in late referred patients, after correction for the presence of the greater initial comorbidity in the late referred patients. However, as already stated before, it is disputable whether correcting for differences in comorbidity at start between early and late referred patients is justified, as LR can be the underlying cause of the higher comorbidity.

These data suggest that there is a more fundamental difference than just the timing of referral or even their difference in comorbidity at start between 'early' and 'late' referred patients. It might be that late referred patients have a different attitude towards their health, e.g. with regard to compliance. It is remarkable, that in late referred patients on PD the outcome deficit in comparison to early referred patients disappears after 1 year of RRT, whereas in late referred patients on HD the weaker outcome remains. It is conceivable that in the PD patients, there is far more attention to education and patient empowerment even in late referred patients. In the same study, mortality was substantially lower in those patients who choose their treatment modality themselves, as compared to patients where the modality was selected by the nephrologist.

All these findings emphasize that 'LR' is more than patients being seen by a nephrologist or not: it is a multi-disciplinary strategy focusing on patient empowerment and education \[[@R44]\]. All these arguments plead to implement the broad rather than the narrow definition of LR and also indicate that nephrological centres should install multi-disciplinary teams to manage these patients.

LR: modality choice, transplantation and vascular access planning {#S6}
=================================================================

Modality selection is influenced by the timing of referral: those patients who are referred to nephrology teams early in the course of their disease are more likely to choose PD rather than HD \[[@R8],[@R39],[@R48]\]. The lack of time before initiation of dialysis results in an information gap in the late referred patient; thus, one finds significantly lower numbers of PD patients amongst late referrals, even after clinical stabilization. This fact directly influences the quality of life of the patients and the cost-effectiveness of the treatment.

As a cause of their clinical condition, LR patients are often condemned to rapid access for initializing dialysis \[[@R36],[@R49],[@R50]\]. Because of the short interval between first contact with a specialist and the initiation of dialysis, an arterio-venous (AV) fistula as permanent vascular access can often not be created in due time \[[@R51]\]. Catheters, either tunnelled or not, are associated with a significantly higher rate of complications and mortality \[[@R52]\]. At least part of the higher mortality in late referred patients is potentially attributable to the use of inferior access strategies \[[@R10]\]. It is important to mention that even after 6 months, the majority of patients started on a tunnelled catheter were still depending on this device as vascular access. It is ill defined whether this is due to refusal of the patient (again pointing to a difference in disease-coping capability and strategies between late and early referred patients) or due to the medical impossibility of creating a fistula, reflecting a higher comorbidity. It should also be kept in mind that in LR patients, vascular access possibilities are often destroyed as no preservation of the 'venous assets' has been implemented.

Once more, focussing only on the narrow, time to dialysis dependent, definition of LR will probably not be much of help to improve problems related to modality choice or access-related morbidity. In the multi-disciplinary programme in Toronto, predialysis access creation was achieved in 86.3% of patients, demonstrating that a planned approach can be helpful \[[@R45],[@R53]\].

Although HD is by far the most often chosen modality of RRT for LR patients, Povlsen *et al*. \[[@R54]\] demonstrated that in their centre, acute start of PD is possible, and gives good short- and long-term results. Lobbedez *et al*. \[[@R55]\] compared the outcome of unplanned PD and HD patients. After correcting for differences in comorbidity, the initial hospitalization duration was similar in HD versus PD patients, as was long-term patient and technique survival. PD was started 8.6 ± 10 days after catheter insertion. As this strategy might prevent patients starting on a non-tunnelled central venous line, this approach could be considered in all patients. However, an 'acute start of PD' programme needs careful planning and dedication from the complete team, from the trainee at the emergency ward, to the nurses and the person placing the Tenckhoff catheter.

LR not only influences modality choice between HD and PD but also impacts on the chances of transplantation. Cass *et al*. \[[@R32],[@R56]\] demonstrated that late referred patients had a twice lower likelihood of being waitlisted for transplantation and a 35% lower likelihood of being transplanted during the first 2 years of their RRT. Winkelmayer *et al*. \[[@R49]\] found a 5-fold lower transplantation rate in LR patients, even after correction for differences in comorbidity and socioeconomic status. Kessler *et al*. \[[@R35]\] found similar results in a 2-year prospective community-based study.

Efficacy and cost-effectiveness of (multi-disciplinary) programmes to fight LR {#S7}
==============================================================================

RRT is expensive and the arising costs are additionally increased by the already existing comorbidity of patients with ESRD and the chosen modality of RRT. LR also results in a lower utilization of cost-saving strategies, such as PD, home-based HD and transplantation.

Lee \[[@R57]\] calculated the costs, including outpatient dialysis care, inpatient care and physician claims, in 166 patients on dialysis therapy for longer than 6 months and found a nearly 50% reduction of cost for PD (∼\$27 000) in comparison to in-patient HD care (\$51 000). These savings come to effect even after switching of dialysis modality from initial therapy with HD to PD \[[@R58]\].

A second cost impact results out of hospitalization \[[@R59]\], its 'intensity' and duration. Costs increase sharply in the last 6 months prior to initiation of dialysis, and hospitalization is a major component of this. As hospitalization is longer in LR patients, and increases with comorbidity, these costs could potentially be avoided by timely management of CKD.

Whereas it is clear that LR increases costs of treatment, it should also not be forgotten that 'early referral' and its related treatment costs are also substantial.

Up to now, it has not been investigated weather costs of management of comorbidities such as renal anaemia and secondary hyperparathyroidism and bone mineral disease will prove to be cost-effective. Whereas there is little doubt about improved outcome by their apt management, their management is expensive \[[@R60]\]. According to the data from the DOPPS, anaemia has proven to be a risk factor independent of comorbid conditions and is associated with higher risks of both hospitalization and death. Collins \[[@R61]\] found that early epoetin treatment to correct renal anaemia appears to be associated with improved survival of ESRD patients in the first year after the start of dialysis and reduced cost of treatment.

There is also indirect evidence that referral to a nephrology unit results in a slowing down of the progression of renal failure \[[@R62]\], thus potentially delaying the start of renal replacement, and thus resulting in substantial cost savings, as renal replacement is itself an expensive treatment. Levin *et al*. \[[@R63]\] reported about the outcomes of two multi-disciplinary predialysis programmes in two major Canadian cities, aiming at a reduction of urgent dialysis starts, improvement of preparedness for dialysis and improvement of resource utilization. The studies demonstrated fewer urgent dialysis starts (13% versus 35%), more outpatient training (76% versus 43%) and less hospital days in the first month of dialysis (6.5 days versus 13.5 days) as well as a success in access creation (86.3% of patients), with estimated cost savings of \$4000 (Canadian dollars) per patient. Goldstein *et al*. \[[@R64]\] describe a better control of blood pressure, renal anaemia, acid--base metabolism and serum albumin in a group of predialysis patients seen by a multi-disciplinary team, resulting in significant superior clinical outcomes.

In a retrospective analysis of 340 patients, Thanamyooran *et al*. demonstrated an improvement in metabolic and blood pressure control, and an increase in the prevalence of PD by the implementation of a multi-disciplinary model \[[@R66]\]. As is demonstrated above, early referral is not sufficient, as also a multi-disciplinary approach \[[@R46]\] is needed to achieve an improvement in functioning vascular access \[[@R65]\] and quality of life \[[@R31]\].

Thanks to a structured predialysis education programme, Goovaerts *et al*. \[[@R67]\] report that 31% of their patients start on PD, 16% on self-care HD and 9% on home HD as initial RRT modality.

However, health economic evaluation of all these interventions is lacking as up till now, and further research is certainly warranted.

The major problems relate to a lack of evidence on the natural evolution of renal function and outcome in this group. The majority of CKD stage 3 patients are far more likely to die from cardiovascular disease than to end up on RRT \[[@R11]\], and even in CKD 4, only 25--30% will need renal replacement. The situation becomes even more complex if one takes into account the normal decline of renal function with age. Taken together, it might be that a lot of effort is invested in 'preparing' patients who never will need RRT. There is an urgent need for a large registry of CKD 4 patients, so that more epidemiologic data on this patient group become available. Without this information, all efforts to claim cost-effectiveness of pre-ESRD care and by extension early referral will remain inaccurate and vague.

Conclusions/suggestions {#S8}
=======================

Although Obrador *et al*. \[[@R68]\] summarized an optimal pre-ESRD care with early detection of progressive renal disease, intervention to retard its progression, prevention of uraemic complications, attenuation of comorbid conditions, adequate preparation for ESRD therapy and timely initiation of RRT already 10 years ago, the numbers of LR patients remain high and unchanged over the past 20 years. This implicates a tremendous socioeconomic impact on the medical systems all over the world.

Several international, national and local initiatives opted to define the point of time of referral as linked to the GFR (broad definition of referral), as the more 'narrow' definition (4 months before start of RRT) is too restrictive and leads too many missed opportunities for intervention in the earlier stages of kidney disease.

Undoubtedly, the sheer number of stage 3 CKD patients would by far overwhelm the existing nephrology care facilities. The management of these numbers will imply a change in paradigm; specialists in nephrology will have to delegate responsibilities to other trained care providers to participate in the care for a growing number of CKD patients. This would also mean a change from the personal 'one-to one' relationship between nephrologist and patient to a more programme-based/clinical pathway-orientated surveillance and care for CKD patients.

With the help of well-informed and well-supported primary care providers as 'screening and detection' agents, the CKD patient could easily be followed up and only be referred to a multi-disciplinary team of a nephrological centre when appropriate and needed. Secondly, the short communication channels within such a team make 'informal information' between caregivers easy and effective, with a minimum of information loss.

The choice of the RRT in the 'late referred' setting has long-lasting consequences for the patient, but the situation does not yield much time for considerations, neither for the medical staff nor for the patient and his or her relatives. The planning and processing of a chronic dialysis access is imperative. Preparation for late start RRT should include a strong encouragement for initiation on PD to avoid unnecessary use of central lines, and the discussion of pre-emptive transplantation of live donors when available.

The goal should be a reduction of LR patients when analysing the single centre\'s situation, and hereby the differentiation between 'avoidable' and 'unavoidable' LR is crucial. A large-scale registry on the fate of CKD 4 patients is urgently warranted to provide evidence for initiatives taken in the field of pre-ESRD care.
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